Bausch Health Companies Inc.
$22.19B- Market cap
- $2.46B
- Debt
- +$21.04B
- Cash
- −$1.31B
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.17x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BHC stock price at discount vs TRGP $6.57 current versus $14.35 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TRGP's multiple
Implied fair value · at BHC's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BHC FY 2025 (ended Dec 31, 2025) · TRGP FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.17x
Capital structure 78% equity / 22% debt · EV / Revenue 4.67x · EV / EBITDA 16.69x
TRGP carries the larger enterprise value at $79.47B against $22.19B; BHC trades on the lower EV / Revenue multiple (2.16x vs 4.67x); BHC on the lower EV / EBITDA (9.17x vs 16.69x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Bausch Health Companies Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
TARGA RESOURCES CORP. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-37.98x
5.68x
Net debt / EBITDA
Leverage against operating earnings
8.15x
3.63x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$166.10M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
KINDER MORGAN, INC.
BHC vs KMI
WILLIAMS COMPANIES, INC.
BHC vs WMB
ONEOK INC /NEW/
BHC vs OKE
ENTERPRISE PRODUCTS PARTNERS L.P.
BHC vs EPD
Energy Transfer LP
BHC vs ET
$21.04B
$17.43B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.